CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

NCT04145349 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Desmoplastic Small Round Cell Tumor

Interventions

DRUG: Ramucirumab
DRUG: Cyclophosphamide
DRUG: Vinorelbine

Sponsor

Eli Lilly and Company